Compositions Against Cancer Antigen Liv-1 and Uses Thereof

Abstract

Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.

1 . A murine antibody that specifically binds a polypeptide or protein encoded by SEQ ID NO:1, wherein the antibody is selected from the group of Table 6. 
     
     
         2 . An antibody which is a chimeric or humanized form of the murine antibody of  claim 1 . 
     
     
         3 . The antibody of  claim 2 , which is a chimeric or humanized form of the antibody 1.7A4, BR2-13a or BR2-19a. 
     
     
         4 . The antibody of  claim 2 , which is a chimeric or humanized form of the antibody 1.7A4. 
     
     
         5 . The antibody of  claim 4 , wherein the chimeric antibody comprises a heavy chain variable region having the amino acid sequence of SEQ ID NO:3 and a light chain variable region having the amino acid sequence of SEQ ID NO:4. 
     
     
         6 . The antibody of  claim 4 , wherein the humanized antibody comprises a heavy chain variable region having the amino acid sequences of the complementarity determining regions of SEQ ID NO:3 and a light chain variable region having the amino acid sequences of the complementarity determining regions of SEQ ID NO:4. 
     
     
         7 . The antibody of  claim 2 , which is a chimeric or humanized form of the antibody 1.1F10. 
     
     
         8 . The antibody of  claim 2 , which is a chimeric or humanized form of the antibody BR2-14a, BR2-15a, BR2-16a, BR2-20a, BR2-21a, BR2-22a, BR2-23a, BR2-24a or BR2-25a. 
     
     
         9 . The antibody of  claim 2 , wherein the chimeric or humanized antibody is conjugated to an effector component. 
     
     
         10 . The antibody of  claim 9 , wherein the effector component is selected from the group consisting of a fluorescent label, a radioisotope or a cytotoxic chemical. 
     
     
         11 . The antibody of  claim 10 , wherein the cytotoxic chemical is auristatin-E or MMAE. 
     
     
         12 . The antibody of  claim 2 , wherein the chimeric or humanized antibody is an antibody fragment. 
     
     
         13 . A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the antibody of  claim 2 . 
     
     
         14 . The pharmaceutical composition of  claim 13 , wherein the antibody is conjugated to an effector component. 
     
     
         15 . The pharmaceutical composition of  claim 14 , wherein the effector component is selected from the group consisting of a fluorescent label, a radioisotope or a cytotoxic chemical. 
     
     
         16 . The pharmaceutical composition of  claim 16 , wherein the cytotoxic chemical is auristatin-E or MMAE. 
     
     
         17 . A method of treating an individual with prostate or breast cancer, the method comprising administering a therapeutically effective dose of the chimeric or humanized antibody of  claim 2 . 
     
     
         18 . The method of  claim 17 , wherein the antibody is a chimeric antibody. 
     
     
         19 . The method of  claim 17 , wherein the antibody is an antibody fragment. 
     
     
         20 . The method of  claim 17 , wherein the antibody is a humanized antibody. 
     
     
         21 . The method of  claim 17 , wherein the antibody is conjugated to an effector component. 
     
     
         22 . The method of  claim 21 , wherein the effector component is selected from the group consisting of a fluorescent label, a radioisotope or a cytotoxic chemical. 
     
     
         23 . A hybridoma producing the antibody of  claim 2 . 
     
     
         24 . The hybridoma of  claim 23 , wherein the hybridoma is selected from the group consisting of ATCC accession number PTA-5705, ATCC accession number PTA-5706 and ATCC accession number PTA-5707.